An increase of the proportion of PD-L1-positive/high samples (defined by an arbitrary threshold of 5%) during neoadjuvant CRT was described by Chiang et al. (PD-L1 expression on cancer cells) [19], Ogura et al. (PD-L1 expression on immune cells but not on cancer cells) [20], and by Chen et al. (PD-L1 expression on cancer cells) [21]; however, changes of the PD-L1 scores were not reported. This evidence concerns the gene CD274 and cancer.